Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Alexander S. Wang & Steven A. Gunzler. (2019) Systematic review of the pharmacoeconomics of Parkinson disease medications. Expert Opinion on Pharmacotherapy 20:13, pages 1659-1670.
Read now
Read now
Evelyn Walter & Per Odin. (2015) Reply: Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s Disease in the UK and Germany. Journal of Medical Economics 18:11, pages 860-862.
Read now
Read now
Gillian Barnett & Adrian C. Williams. (2015) Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s Disease in the UK and Germany. Journal of Medical Economics 18:11, pages 858-859.
Read now
Read now
Carmen Rodríguez-Blázquez, Maria João Forjaz, Luis Lizán, Silvia Paz & Pablo Martínez-Martín. (2015) Estimating the direct and indirect costs associated with Parkinson’s disease. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 889-911.
Read now
Read now
Francisco Grandas. (2013) Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease. Expert Review of Neurotherapeutics 13:12, pages 1343-1353.
Read now
Read now
Articles from other publishers (25)
Sara Abidar, Lucian Hritcu & Mohamed Nhiri. (2023) The Natural Neuroprotective Compounds Used in the 6-Hydroxydopamine-
Induced Parkinson’s Disease in Zebrafish: The Current
Applications and Perspectives. CNS & Neurological Disorders - Drug Targets 22:10, pages 1472-1483.
Crossref
Crossref
Fabien Zagnoli, Amélie Leblanc, Irina Viakhireva-Dovganyuk, Jean-Philippe Delabrousse-Mayoux, Alain Pouyet, Marc Ziegler, Laura Sogni, Marie Patat, Régis Bouillot, Marc Vérin, Andrei Arhire, Philippe Barres, Maxime Blondiaux, Jean-Claude Bouffeteau, Jean-Philippe Brandel, Christophe Carel, Giovanni Castelnovo, Marc Coustans, Lucie Courault, Christian Crauser, Isabelle Degaey, Bertrand Degos, Jean-Philippe Delabrousse, Béatrice Denis, Marie-Claude Dourneau, Arnaud Duretete, Jean-Marc François Feve, Erika Follin, Michel Gugenheim, Cécile Hubsch, Nathalie Patte Karsenti, Pierre Louchart, Serge Massengo, José Mejias, Homero Monteiro, Philippe Muh, Bernard Pedespan, Virginie Sattler, Mathieu Sevin, Mélissa Tir, Anne Tirel Badets, Marc Verin, Irina Viakhireva, Elisabeth Vidry & Jean-Charles Wiart. (2023) Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study. Journal of Neural Transmission 130:11, pages 1463-1474.
Crossref
Crossref
F. Zagnoli, M. Vérin, A. Tirel, M. Tir, F. Ory-Magne, A. Marques, D. Maltête, S. Frismand, F. Fluchère, S. Drapier, L. Defebvre, R. Decombe, M. Bereau & S. Bannier. (2023) La perfusion sous-cutanée d’apomorphine : recommandations à destination des acteurs de santé pour une installation à l’hôpital ou à domicile. Pratique Neurologique - FMC 14:2, pages 90-97.
Crossref
Crossref
Nouara Yahi, Coralie Di Scala, Henri Chahinian & Jacques Fantini. (2021) Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson’s disease. Glycoconjugate Journal 39:1, pages 1-11.
Crossref
Crossref
Katarzyna Smilowska, Daniel J. van Wamelen, Tomasz Pietrzykowski, Alexander Calvano, Carmen Rodriguez-Blazquez, Pablo Martinez-Martin, Per Odin & K. Ray Chaudhuri. (2021) Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review. Journal of Parkinson's Disease 11:2, pages 475-489.
Crossref
Crossref
D. van Poppelen, V. Sisodia, R. J. de Haan, M. G. W. Dijkgraaf, P. R. Schuurman, G. J. Geurtsen, A. E. M. Berk, R. M. A. de Bie & J. M. Dijk. (2020) Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson’s disease - the INfusion VErsus STimulation (INVEST) study. BMC Neurology 20:1.
Crossref
Crossref
Elisa Gomez-Inhiesto, María Teresa Acaiturri-Ayesta, Iker Ustarroz-Aguirre, Diana Camahuali, Maider Urtaran-Laresgoiti, Marisol Basabe-Aldecoa, Roberto Nuño-Solinís & Elena Urizar. (2020) Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies. Parkinson's Disease 2020, pages 1-6.
Crossref
Crossref
Shirley D. Wenker & Fernando J. Pitossi. (2019) Cell therapy for Parkinson′s disease is coming of age: current challenges and future prospects with a focus on immunomodulation. Gene Therapy 27:1-2, pages 6-14.
Crossref
Crossref
A.L. Sette, E. Seigneuret, F. Reymond, S. Chabardes, A. Castrioto, B. Boussat, E. Moro, P. François & V. Fraix. (2019) Battery longevity of neurostimulators in Parkinson disease: A historic cohort study. Brain Stimulation 12:4, pages 851-857.
Crossref
Crossref
Naveed Malek. (2019) Deep Brain Stimulation in Parkinson's Disease. Neurology India 67:4, pages 968.
Crossref
Crossref
Bruno Spindola, Marco Antônio Leite, Marco Orsini, Erich Fonoff, José Alberto Landeiro & Bruno Lima Pessoa. (2017) Ablative surgery for Parkinson’s disease: Is there still a role for pallidotomy in the deep brain stimulation era?. Clinical Neurology and Neurosurgery 158, pages 33-39.
Crossref
Crossref
Johan Virhammar & Dag Nyholm. (2016) Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience. Therapeutic Advances in Neurological Disorders 10:3, pages 171-187.
Crossref
Crossref
Rolf Salvesen. (2017) Kostbar behandling ? likeverdig behandling?. Tidsskrift for Den norske legeforening 137:9, pages 592-592.
Crossref
Crossref
Beriwan Ezat, Lasse Pihlstrøm, Jan Aasly, Ole-Bjørn Tysnes, Arild Egge & Espen Dietrichs. (2017) Bruk av avansert behandling ved Parkinsons sykdom i Norge. Tidsskrift for Den norske legeforening 137:9, pages 619-623.
Crossref
Crossref
Chi Zhang, Xianrui Yuan, Zhongliang Hu, Songlin Liu, Haoyu Li, Ming Wu, Jian Yuan, Zijin Zhao, Jun Su, Xiangyu Wang, Yiwei Liao & Qing Liu. (2017)
Valproic Acid Protects Primary Dopamine Neurons from MPP
+
-Induced Neurotoxicity: Involvement of GSK3
β
Phosphorylation by Akt and ERK through the Mitochondrial Intrinsic Apoptotic Pathway
. BioMed Research International 2017, pages 1-12.
Crossref
Crossref
Tomasz Fundament, Paul R. Eldridge, Alexander L. Green, Alan L. Whone, Rod S. Taylor, Adrian C. Williams & W. M. Michael Schuepbach. (2016) Deep Brain Stimulation for Parkinson?s Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis. PLOS ONE 11:7, pages e0159340.
Crossref
Crossref
R. García-Ramos, E. López Valdés, L. Ballesteros, S. Jesús & P. Mir. (2016) The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain. Neurología (English Edition) 31:6, pages 401-413.
Crossref
Crossref
R. García-Ramos, E. López Valdés, L. Ballesteros, S. Jesús & P. Mir. (2016) Informe de la Fundación del Cerebro sobre el impacto social de la enfermedad de Parkinson en España. Neurología 31:6, pages 401-413.
Crossref
Crossref
Dhanya Vijayakumar & Joseph Jankovic. (2016) Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs 76:7, pages 759-777.
Crossref
Crossref
Luca Degli Esposti, Carlo Piccinni, Diego Sangiorgi, Flavio Nobili & Stefano Buda. (2015) Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. Neurological Sciences 37:2, pages 227-234.
Crossref
Crossref
Maria I. VenturaJerri D. EdwardsDeborah E. Barnes. (2015) More than just a movement disorder. Neurology 85:21, pages 1828-1829.
Crossref
Crossref
Robert Bauer & Alireza Gharabaghi. 2015. Handbook of Neuroethics. Handbook of Neuroethics
977
992
.
Jerrold L VitekJoachim K KraussGötz Lütjens. 2014. Deep Brain Stimulation: Technology and Applications (Volume 1). Deep Brain Stimulation: Technology and Applications (Volume 1)
6
19
.
Mariachiara Sensi, F. Preda, L. Trevisani, E. Contini, D. Gragnaniello, J. G. Capone, E. Sette, N. Golfre-Andreasi, V. Tugnoli, M. R. Tola & R. Quatrale. (2014) Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. Journal of Neural Transmission 121:6, pages 633-642.
Crossref
Crossref
Paul F Worth. (2013) When the going gets tough: how to select patients with Parkinson's disease for advanced therapies. Practical Neurology 13:3, pages 140-152.
Crossref
Crossref